home / stock / evok / evok news

EVOK News and Press, Evoke Pharma Inc. From 04/19/23

Stock Information
Company Name: Evoke Pharma Inc.
Stock Symbol: EVOK
Market: NASDAQ
Website: evokepharma.com
Menu
EVOK EVOK Quote EVOK Short EVOK News EVOK Articles EVOK Message Board
Get EVOK Alerts

News, Short Squeeze, Breakout and More Instantly...
EVOK - Vyne, Ensysce top healthcare gainers; Allarity, Femasys lead losers' pack

2023-04-19 10:05:08 ET Gainers: Vyne Therapeutics ( VYNE ) +32% . Ensysce Biosciences ( ENSC ) +23% . Legend Biotech ( LEGN ) +20% . Tempest Therapeutics ( TPST ) +16% . Evoke Pharma ( EVOK ) +14% . Losers: Allarity T...
EVOK - Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI-Related Patent

SOLANA BEACH, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, announced the United States Patent ...

EVOK - Evoke Pharma & EVERSANA Announce Compelling Real-World Data on the Impact of GIMOTI in Reducing the Utilization of Healthcare Resources to be Presented at the Academy of Managed Care Pharmacy (AMCP) 2023

SOLANA BEACH, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, and EVERSANA Life ...

EVOK - Evoke Pharma, Inc. (EVOK) Q4 2022 Earnings Call Transcript

2023-03-21 18:39:15 ET Evoke Pharma, Inc. (EVOK) Q4 2022 Earnings Conference Call March 21, 2023, 04:30 PM ET Company Participants Daniel Kontoh-Boateng - Investor Relations David Gonyer - Chief Executive Officer Chris Quesenberry - GIMOTI's Chief Commercial Offi...
EVOK - Evoke Pharma GAAP EPS of $0.54 beats by $1.07, revenue of $0.79M misses by $0.1M

2023-03-21 16:24:52 ET Evoke Pharma press release ( NASDAQ: EVOK ): Q4 GAAP EPS of $0.54 beats by $1.07 . Revenue of $0.79M (+119.4% Y/Y) misses by $0.1M . Total operating expenses for the fourth quarter of 2022 were approximately $2.3 million compared with $1....

EVOK - Evoke Pharma Reports Fourth Quarter and Full Year 2022 Financial Results

Fiscal year 2022 net product sales from prescriptions increased by 179% to $2.5 million versus 2021 Patient enrollment increased by 149% compared with 2021 SOLANA BEACH, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASD...

EVOK - Evoke Pharma to Report Fourth Quarter and Full Year 2022 Results on March 21, 2023

SOLANA BEACH, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, today announced that the C...
EVOK - CZOO and EVOK among mid-day movers

2023-03-10 12:40:14 ET Gainers: Euda ( EUDA ) +94% . Altamira Therapeutics ( CYTO ) +40% . Unicycive ( UNCY ) +37% . Cazoo Group ( CZOO ) +27% . Tenon Medical ( TNON ) +20% . PLAYSTUDIOS ( MYPS ) +19% . Solo Brand...

EVOK - Evoke Pharma and EVERSANA Selected to Present Results of Real-World Healthcare Utilization Study Comparing GIMOTI® and Oral Metoclopramide at the Digestive Disease Week Plenary Session

SOLANA BEACH, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI ® (metoclopramide) nasal spray, and EVERSANA™, a lead...

EVOK - Evoke stock rises on filing of dismissal in nasal spray Gimoti's patent infringement case

Evoke Pharma ( NASDAQ: EVOK ) stock rose ~4% on Monday after the company said that a joint stipulation of dismissal was filed in the Gimoti's patent infringement case in the U.S. District Court for the District of New Jersey. The filing of the stipulation arises fro...
Previous 10 Next 10